Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation

What Was Tested

The paper reports a study of ACTH (Corticotropin), published as a clinical trial.

To investigate the safety of adrenal vein sampling, the cutoff values for the selectivity and lateralization indexes, and the effect of adrenocorticotropic hormone stimulation on selectivity index and lateralization index performance.

Why It Was Studied

Adrenal vein sampling is crucial for identifying the primary aldosteronism subtypes, but the cutoff values for ascertaining selectivity of catheterization and lateralization of aldosterone secretion remain controversial.

Who Took Part

According to the abstract, 151 patients were involved.

PubMed indexes the participants as middle-aged adults, both men and women.

The researchers assessed the proportion of selective adrenal vein sampling at different selectivity index cutoff values in 151 consecutive patients with primary aldosteronism undergoing bilaterally simultaneous adrenal vein sampling.

In 44 patients with bilaterally selective adrenal vein sampling and unequivocal diagnosis of aldosterone-producing adenoma on the basis of all these criteria, the researchers examined the cutoff values of the lateralization index for assessing the lateralization of aldosterone excess and the effect of adrenocorticotropic hormone stimulation on selectivity index and lateralization index.

What Was Measured

Adrenal vein sampling is crucial for identifying the primary aldosteronism subtypes, but the cutoff values for ascertaining selectivity of catheterization and lateralization of aldosterone secretion remain controversial.

Topics PubMed links to this paper include Adrenal Gland Neoplasms, Adrenal Glands, Adrenocortical Adenoma, Adrenocorticotropic Hormone, Aldosterone, Catheterization and Cohort Studies.

What This Means in Plain Language

This is a clinical trial of ACTH (Corticotropin) in 151 patients.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Journal of hypertension), a journal based in Netherlands.

More context: the ACTH (Corticotropin) compound page, all human trials.